Lancet Gastroenterology & Hepatology

Article	Citations
Liver injury in COVID-19: management and challenges	1324
Prolonged presence of SARS-CoV-2 viral RNA in faecal samples	1257
Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis	750
The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis	632
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis	472
SARS-CoV-2 in wastewater: potential health risk, but also data source	376
Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis	363
COVID-19 and the liver: little cause for concern	319
Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-labe	303
Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis	265
Early detection of pancreatic cancer	255
Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis	240
Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population-based study	236
Implications of COVID-19 for patients with pre-existing digestive diseases	235
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study	231
The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease St	226
Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach	213
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, pha	209
Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019	203
The rising tide of early-onset colorectal cancer: a comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection	202
COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy	196
Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study	188
Global, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019	181
Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study	153
A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study	147

Effect of COVID-19 lockdown on alcohol consumption in patients with pre-existing alcohol use disorder	145
Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis	143
Antibiotic use and the development of inflammatory bowel disease: a national case-control study in Sweden	142
Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial	137
Global multi-stakeholder endorsement of the MAFLD definition	135
Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis	133
Probiotics and COVID-19: one size does not fit all	132
Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement	128
Redefining fatty liver disease: an international patient perspective	123
Colorectal cancer in Crohn's disease: a Scandinavian population-based cohort study	122
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial	120
Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis	118
Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours: a multicentre, open-label, randomised controlled trial	118
Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis	118
Enteric involvement in hospitalised patients with COVID-19 outside Wuhan	117
Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis	114
Robotic versus laparoscopic surgery for middle and low rectal cancer (REAL): short-term outcomes of a multicentre randomised controlled trial	113
Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, par	111
Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial	108
Global prevalence of functional constipation according to the Rome criteria: a systematic review and meta-analysis	107
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial	106
Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel	105
Ultra-processed foods and human health: from epidemiological evidence to mechanistic insights	105
SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement	103
Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver dise	102
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study	101
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial	100
Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial	100
Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa	100
The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease	99
Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study	96
Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study	96
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomi	93
Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis	92
Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study	91
Severe acute hepatitis in children: investigate SARS-CoV-2 superantigens	86
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority st	86
Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial	84
Preoperative oral antibiotics and surgical-site infections in colon surgery (ORALEV): a multicentre, single-blind, pragmatic, randomised controlled trial	83
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm,	82
The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial	82
Determining risk factors for mortality in liver transplant patients with COVID-19	82
Gastrointestinal sequelae 90 days after discharge for COVID-19	81
Current and emerging therapies for advanced biliary tract cancers	79
Obesity: another ongoing pandemic	79
Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study	78
Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial	78
Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium	77
Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study	74
Risk of colorectal cancer incidence and mortality after polypectomy: a Swedish record-linkage study	73

Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement	73
Implications of gastrointestinal manifestations of COVID-19	72
Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines	72
Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China	71
Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period	69
Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis	68
Breaking the therapeutic ceiling in drug development in ulcerative colitis	68
The global, regional, and national burden of gastro-oesophageal reflux disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017	67
COVID-19 in liver transplant recipients: preliminary data from the ELITA/ELTR registry	67
Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis	67
Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial	67
Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis	66
Global reporting of progress towards elimination of hepatitis B and hepatitis C	66
Standard gastroenterologist versus multidisciplinary treatment for functional gastrointestinal disorders (MANTRA): an open-label, single-centre, randomised controlled trial	65
Computer-aided detection versus advanced imaging for detection of colorectal neoplasia: a systematic review and network meta-analysis	65
The knowns and unknowns of treatment for alcoholic hepatitis	64
Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis	61
Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment: a prospective controlled study	61
Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial	61
Drinking alone: COVID-19, lockdown, and alcohol-related harm	60
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives	59
Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey	59
Green endoscopy: a call for sustainability in the midst of COVID-19	59
Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial	58
Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial	57
The overlap between irritable bowel syndrome and organic gastrointestinal diseases	56
Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review	56
The effect of sleep on gastrointestinal functioning in common digestive diseases	56
Transmural healing as a therapeutic goal in Crohn's disease: a systematic review	56
Inflammation and malnutrition in inflammatory bowel disease	55
Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases	55
Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis	54
Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): 10-year follow-up of an open-label, non-inferiority, randomised controlled trial	54
Adaptations in gastrointestinal physiology after sleeve gastrectomy and Roux-en-Y gastric bypass	51
Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised tr	51
Liver transplantation in patients with alcohol-related liver disease: current status and future directions	50
The impact of COVID-19 on hepatitis elimination	50
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept t	50
Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study	50
Screening FMT donors during the COVID-19 pandemic: a protocol for stool SARS-CoV-2 viral quantification	49
The economic burden of colorectal cancer across Europe: a population-based cost-of-illness study	49
Tumour-specific fluorescence-guided surgery for pancreatic cancer using panitumumab-IRDye800CW: a phase 1 single-centre, open-label, single-arm, dose-escalation study	49
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial	49
Efficacy and safety of spore-forming probiotics in the treatment of functional dyspepsia: a pilot randomised, double-blind, placebo-controlled trial	48
Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by	48
SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question	48
The intestinal barrier in disorders of the central nervous system	48
Serrated polyp detection and risk of interval post-colonoscopy colorectal cancer: a population-based study	47
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study	46
The effect of a microbial ecosystem therapeutic (MET-2) on recurrent Clostridioides difficile infection: a phase 1, open-label, single-group trial	46
Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium	46
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial	45
Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a populat	45
Effect of a deep learning-based system on the miss rate of gastric neoplasms during upper gastrointestinal endoscopy: a single-centre, tandem, randomised controlled trial	45
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials	45
Diversity in clinical trials: an opportunity and imperative for community engagement	44
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial	44
Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial	43
Drug-induced liver injury in older people	43
Prevention of SARS-CoV-2 infection in patients with decompensated cirrhosis	42
Efficacy of surgical or endoscopic treatment of idiopathic achalasia: a systematic review and network meta-analysis	42
Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled,	42
A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial	41
Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study	41
Predicting endoscopic activity recovery in England after COVID-19: a national analysis	41
Prevention and treatment of nutritional complications after bariatric surgery	40
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled	40
Non-alcoholic fatty liver disease in non-obese individuals: the impact of metabolic health	40
Stigma and irritable bowel syndrome: a taboo subject?	40
Aggressive fluid hydration plus non-steroidal anti-inflammatory drugs versus non-steroidal anti-inflammatory drugs alone for post-endoscopic retrograde cholangiopancreatography pancreatitis (FLUYT): a	39
The role of mucins in gastrointestinal barrier function during health and disease	39
One-food versus six-food elimination diet therapy for the treatment of eosinophilic oesophagitis: a multicentre, randomised, open-label trial	39
The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis	39
Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2–cT3 rectal adenocarcinoma (O	37
Common mental disorders in irritable bowel syndrome: pathophysiology, management, and considerations for future randomised controlled trials	37
Adjuvant 131I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial	37
Sleep and liver disease: a bidirectional relationship	37
Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis	36
Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework	36
Roles of the gut virome and mycobiome in faecal microbiota transplantation	35

Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study	35
Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial	35
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14)	35
Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial	35
Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus	35
Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroentero	34
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study	34
Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study	34
Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial	33
Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease	33
Diabetes following acute pancreatitis	32
Redefining non-alcoholic fatty liver disease: what's in a name?	32
Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study	32
Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak	32
Non-steroidal anti-inflammatory drugs, intravenous fluids, pancreatic stents, or their combinations for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic	32
The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission	32
Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery (UPGRADE): a multicentre, double-blind, randomised, placebo-controlled superiority trial	32
Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective	31
Small molecule oral targeted therapies in ulcerative colitis	31
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study	31
Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomis	31
Barriers to the management of alcohol use disorder and alcohol-associated liver disease: strategies to implement integrated care models	31
Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia	31
A procalcitonin-based algorithm to guide antibiotic use in patients with acute pancreatitis (PROCAP): a single-centre, patient-blinded, randomised controlled trial	31
Glecaprevir–pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies—a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-	31
British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis	31
Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group	30
Probiotics and COVID-19	30
Colorectal cancer screening in the USA in the wake of COVID-19	30
Extensive peritoneal lavage with saline after curative gastrectomy for gastric cancer (EXPEL): a multicentre randomised controlled trial	30
Once-only colonoscopy or two rounds of faecal immunochemical testing 2 years apart for colorectal cancer screening (SCREESCO): preliminary report of a randomised controlled trial	30
Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study	28
Screening faecal microbiota transplant donors for SARS-CoV-2 by molecular testing of stool is the safest way forward	28
Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study	28
The phases of hepatitis C elimination: achieving WHO elimination targets	27
The role of precision nutrition in the modulation of microbial composition and function in people with inflammatory bowel disease	27
Global hepatitis C elimination: an investment framework	27
Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study	27
Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma	27
The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas	27
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial	26
Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study	26
A model of the economic benefits of global hepatitis C elimination: an investment case	26
Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study	26
Fully automated magnetically controlled capsule endoscopy for examination of the stomach and small bowel: a prospective, feasibility, two-centre study	26
Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase	26
Increasing burden of colorectal cancer in China	26
Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicent	26
The relationship between gastrointestinal cancers and the microbiota	25
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study	25
From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative	25
Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy in the treatment of perianal fistulas in Crohn's disease (PISA-II): a patient preference randomised trial	25
Resuming liver transplantation amid the COVID-19 pandemic	25
Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial	24
Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial	24
Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial	24
Self-expandable metal stents versus endoscopic balloon dilation for the treatment of strictures in Crohn's disease (ProtDilat study): an open-label, multicentre, randomised trial	24
Do the most heavily burdened countries have the right policies to eliminate viral hepatitis B and C?	24
Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial	23
Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial	23
Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis	23
Epidemiology, risk factors, social determinants of health, and current management for non-alcoholic fatty liver disease in sub-Saharan Africa	23
Impact of hepatitis C virus point-of-care RNA viral load testing compared with laboratory-based testing on uptake of RNA testing and treatment, and turnaround times: a systematic review and meta-analy	23
Pancreatic cancer: a state of emergency?	23
Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial	22
Effect of prophylactic endoscopic clip placement on clinically significant post-endoscopic mucosal resection bleeding in the right colon: a single-centre, randomised controlled trial	22
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension	22
Effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias: a systematic review and individual patient data meta-analysis	22
Deep neural network for video colonoscopy of ulcerative colitis: a cross-sectional study	22
Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis	21
Anal cancer and precancerous lesions: a call for improvement	21
Peroral endoscopic myotomy versus pneumatic dilation in treatment-naive patients with achalasia: 5-year follow-up of a randomised controlled trial	21
Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study	20
Update on the mesentery: structure, function, and role in disease	20
USPSTF recommends expansion of colorectal cancer screening	20
Faecal immunochemical testing in the COVID-19 era: balancing risk and costs	20
Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial	20
Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial	20
Fatty change of the pancreas: the Pandora's box of pancreatology	19
Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system	19
Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial	19
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of	19
Investigation and management of Wilson's disease: a practical guide from the British Association for the Study of the Liver	19
Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial	19
Safety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: a randomised, double-blind, active-comparator, non-inferiority clinical trial	19
Effect of the COVID-19 pandemic on viral hepatitis services in sub-Saharan Africa	19
Classifying perianal fistulising Crohn's disease: an expert consensus to guide decision-making in daily practice and clinical trials	19
Probiotics and COVID-19	18
Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial	18
Prevalence of occult hepatitis B virus infection in adults: a systematic review and meta-analysis	18
Surgical versus non-surgical management for patients with malignant bowel obstruction (S1316): a pragmatic comparative effectiveness trial	17
Cascade of care during the first 36 months of the treatment as prevention for hepatitis C (TraP HepC) programme in Iceland: a population-based study	17
Enhanced recovery for liver transplantation: recommendations from the 2022 International Liver Transplantation Society consensus conference	17
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial	17
Resuming liver transplantation amid the COVID-19 pandemic	17